However, they have limitations, including smaller participant groups and limited study periods
The GLP-1 agonist era beginning with liraglutide (Saxenda) marked a paradigm shift toward medications that worked with the bodys natural appetite regulation systems rather than against them
In a clinical cohort of 2,918 participants, fasting levels of GBB were dose-dependently associated with prevalence of CVD, coronary artery disease (CAD), and peripheral artery disease (PAD), even after adjusting for traditional risk factors
By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy
47 , D442D450 (2019)
However, it is important to monitor the levels of the sex steroid hormones as well as DHEA-S during supplementation just like with too little DHEA, too much DHEA (and/or DHEA-S) can have its own set of distressing symptoms